The present invention is to provide a novel heterocyclic compound of the formula [I]: ##STR00001## wherein R.sup.1 is a halogen, nitro, an alkyl, etc.; R.sup.2 is hydrogen, an alkyl, etc.; Ring A is 2-oxo-4-imidazolin-3,4-diyl, etc.; Ring B is a cycloalkyl, monocyclic saturated heterocyclic group; X is CH, N; Y is a single bond, CO, SO.sub.2; Z is O, NH, etc.; and Ring C is an aryl, a heterocyclic group, or a pharmaceutically acceptable salt thereof, which is useful as a p38 MAP kinase inhibitor.